-
Indatuximab: Advancing CD138-Targeted Therapy in Cancer Research(Post)
What You Need to Know About IndatuximabWhat is Indatuximab?Indatuximab ravtansine is an experimental monoclonal antibody-drug conjugate (ADC) that targets CD138, a protein highly express
CD25+FOXP3+CD45RA- Treg Cells and Cancer Prognosis(Post)The Role of CD25+FOXP3+CD45RA- Treg Cells in Cancer PrognosisIntroductionRegulatory T-cells (Treg cells) are a specialized subset of T-cells that play a pivotal role in maintaining immune homeostasis
Polatuzumab: Redefining Targeted Therapies in B-Cell Lymphoma(Post)What You Need to Know About PolatuzumabWhat is Polatuzumab??Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b, a component of the B-cell receptor, used primarily in B-cel
Prevention and Risk Mitigation: Strategies to Reduce Hantavirus Exposure in a Changing World(Post)As hantavirus cases continue to rise globally, the question becomes not just how to detect infections, but how to prevent them in the first place. Recent epidemiological investigations across Califor
Obinutuzumab: Advancing Targeted Therapy in Hematologic Cancers(Post)Quick Facts About ObinutuzumabWhat is Obinutuzumab?Obinutuzumab is a monoclonal antibody targeting CD20, primarily used in treating B-cell malignancies such as chronic lymphocytic leukem
Brentuximab: Unveiling the Role of Anti-CD30 in Cancer Research(Post)Key Facts About BrentuximabWhat is Brentuximab?Brentuximab is a monoclonal antibody targeting CD30, commonly used in the treatment of Hodgkin lymphoma and systemic anaplastic large cell
Mitochondrial Transfer: A Novel Immune Evasion Mechanism in Cancer(Post)In the intricate dance between the immune system and cancer, tumors often deploy cunning strategies to evade destruction. A groundbreaking 2025 study in Nature has unveiled a startling new tactic: can
Renal Cell Carcinoma: Understanding, Diagnosing, and Treating Kidney Cancer(Post)Renal Cell Carcinoma (RCC) is the most common form of kidney cancer, originating in the lining of the proximal renal tubules. RCC accounts for approximately 90% of all kidney cancers and
Phosphorothioate: Enhancing Stability in Oligonucleotide-Based Therapies(Post)Phosphorothioate is a chemical modification commonly used in oligonucleotide-based therapies to enhance the stability and efficacy of therapeutic nucleic acids. In this modification, one
Gemtuzumab: Advancing CD33-Targeted Therapies in AML Research(Post)Key Facts About GemtuzumabWhat is Gemtuzumab?Gemtuzumab is an antibody-drug conjugate (ADC) targeting CD33, a protein expressed on the surface of myeloid cells. It is widely recognized f
Ifabotuzumab: Exploring the Role of Anti-EphA3 in Cancer Research(Post)What You Need to Know About IfabotuzumabWhat is Ifabotuzumab?Ifabotuzumab is a monoclonal antibody targeting EphA3, a receptor tyrosine kinase overexpressed in certain cancers. It plays
CD39: A Novel Target to Overcome Immunosuppression in Cancer(Post)Introduction to CD39 and Cancer Immunosuppression CD39 is an ectonucleotidase enzyme that plays a crucial role in generating adenosine, a powerful immunosuppressive molecule within the tu
Denosumab: A Comprehensive Overview of Mechanism, Applications, and Research Advances(Post)Biologics · Bone MetabolismDenosumab: RANKL Inhibition, Clinical Applications and BiosimilarsDenosumab is a fully human monoclonal antibody against RANKL, the cytokine that drives osteoclast formation
Mycoplasma Troubleshooting Tips & FAQ(Page) Enoblituzumab: Unveiling the Role of Anti-B7-H3 in Cancer Research(Post)Key Facts About EnoblituzumabWhat is Enoblituzumab?Enoblituzumab is a monoclonal antibody targeting the B7-H3 protein, which is expressed on the surface of various cancer cells, includin
Utomilumab: Advancing Immuno-Oncology Research(Post)Quick Facts About UtomilumabWhat is Utomilumab?Utomilumab is a monoclonal antibody targeting 4-1BB (CD137), a co-stimulatory receptor on T-cells, designed to enhance anti-tumor immunity.
Top 10 Therapeutics(Page) Subcellular Fractionation Protocol - Mitochrondria, Nuclear, Cytosolic(Page) Girentuximab: Exploring Its Mechanism, Clinical Potential, and Research Advancements(Post)Quick Facts About GirentuximabWhat is Girentuximab?Girentuximab is a monoclonal antibody targeting carbonic anhydrase IX (CAIX), predominantly expressed in renal cell carcinoma (RCC) cel
Tidutamab: Unlocking the Potential of SSTR2-Targeting in Oncology Research(Post)Quick Facts About TidutamabWhat is Tidutamab?Tidutamab is a monoclonal antibody designed to target somatostatin receptor 2 (SSTR2), a key protein involved in various neuroendocrine tumor
Bococizumab: Mechanism, Clinical Applications, and Biosimilars in Research(Post)Quick Facts About BococizumabWhat is Bococizumab?Bococizumab is a monoclonal antibody that targets PCSK9, a protein involved in cholesterol regulation.How Does Bococizumab Work?It inhibi
Iscalimab: Advancing Research in Autoimmune Diseases and Transplantation(Post)What You Need to Know About IscalimabWhat is Iscalimab?Iscalimab (CFZ533) is a monoclonal antibody targeting CD40, a key protein involved in immune system regulation.What is the mechanis
Non-Small Cell Lung Carcinoma: Understanding, Diagnosing, and Treating NSCLC(Post)Non-Small Cell Lung Carcinoma (NSCLC) is the most common type of lung cancer, representing about 85% of all lung cancer cases. NSCLC includes several subtypes, with distinct biological ch
Ponsegromab: A Breakthrough in Heart Failure and Cachexia Research(Post)Quick Facts About PonsegromabWhat is Ponsegromab?Ponsegromab is an investigational monoclonal antibody developed by Pfizer, primarily studied for its potential in treating heart failure
T-Cell Co-Stimulation and Agonist Checkpoint Signalling Explained(Post)Signal 1 tells a T cell what it is looking at; signal 2 tells it whether to care. The same peptide–MHC engagement that launches a productive effector response can just as easily install an anergy pro
TNFR2: Taming Regulatory T Cells to Enhance Anti-Tumor Immunity(Post)In recent years, cancer immunotherapy has become a powerful tool for treating various malignancies. One promising approach involves targeting the tumor microenvironment, particularly regu
Enavatuzumab: Revolutionizing Cancer Research Through Novel Therapeutics(Post)Quick Facts About EnavatuzumabWhat is Enavatuzumab?Enavatuzumab is a monoclonal antibody targeting the TWEAK receptor (Fn14), pivotal in tumor growth and immune regulation.What is the me
Avizakimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About AvizakimabWhat is Avizakimab?Avizakimab is a monoclonal antibody designed to target the CD47 protein, a key checkpoint in immune regulation, particularly in cancer ther
Tomaralimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About TomaralimabWhat is Tomaralimab?Tomaralimab is an anti-CD47 monoclonal antibody designed to enhance immune system recognition of cancer cells by blocking the "don't eat
Neuroinflammation and Compulsive Behavior: The Role of Astrocytes in OCD(Post)Imagine a mind trapped in a loop, endlessly repeating actions or thoughts, driven by an invisible force. For millions worldwide, this is the reality of Obsessive-Compulsive Disorder (OCD). While trad
Beyond Burnout: How T Cell Exhaustion Hijacks Cancer Immunity and What We Can Do About It(Post)Imagine a highly trained soldier, elite and effective, sent to the front lines of a relentless war. Day after day, they fight without rest, their supplies dwindle, and the enemy never stops coming. Ev
Targeting IL-10R: Enhancing Immune Activation in Cancer(Post)Introduction to IL-10R and Immune Suppression in CancerThe interleukin-10 receptor (IL-10R) is a key player in regulating immune responses, particularly in suppressing inflammation and ma
Lirilumab: Unlocking the Potential of Anti-KIR Therapy in Cancer Research(Post)Quick Facts About LirilumabWhat is Lirilumab?Lirilumab is an anti-KIR monoclonal antibody designed to enhance natural killer (NK) cell activity by blocking killer-cell immunoglobulin-lik
Varlilumab: Unlocking CD27’s Potential in Cancer Research(Post)What You Need to Know About VarlilumabWhat is Varlilumab?Varlilumab is a monoclonal antibody targeting CD27, a receptor on T-cells that plays a critical role in immune modulation.What is
Vesencumab: Unlocking the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About VesencumabWhat is Vesencumab?Vesencumab is an experimental monoclonal antibody designed to target CD47, a key regulator of immune evasion in cancer cells.How Does Vesen
Vibostolimab: Mechanism, Clinical Applications, and Research Potential in Oncology(Post)Key Facts About VibostolimabWhat is Vibostolimab?Vibostolimab is an anti-TIGIT monoclonal antibody developed by Merck, targeting immune checkpoint pathways to enhance anti-tumor immunity
Lusvertikimab: Unveiling the Potential in Immuno-Oncology(Post)What You Need to Know About LusvertikimabWhat is Lusvertikimab?Lusvertikimab is a monoclonal antibody designed to inhibit the IL-4 receptor, a key player in regulating immune responses,
Troubleshooting high ELISA concentrations(Post)QUICK ANSWER If your ELISA returns sample concentrations that are orders of magnitude too high, the assay itself is usually fine — the error is almost always in data analysis. The most
Business Development Manager, UK(Page) Ianalumab: Exploring Its Mechanism, Clinical Applications, and Research Potential(Post)Quick Facts About IanalumabWhat is Ianalumab?Ianalumab is a monoclonal antibody currently being investigated for its potential in treating autoimmune diseases, particularly lupus and imm
Bevacizumab: Mechanism, Clinical Applications, and Biosimilar Insights(Post)Quick Facts About BevacizumabWhat is Bevacizumab?Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis (the formation of ne
Ulocuplumab: Targeting CXCR4 in Cancer Research and Beyond(Post)Quick Facts About UlocuplumabWhat is Ulocuplumab?Ulocuplumab is an investigational monoclonal antibody targeting CXCR4, a chemokine receptor involved in tumor progression and immune cell
Begelomab: Mechanism of Action, Clinical Applications & Biosimilars(Post)Quick Facts About BegelomabWhat is Begelomab?Begelomab is a monoclonal antibody that targets CD26, a key molecule involved in immune regulation. It has been studied for its potential app
Litifilimab: A Promising Anti-BDCA2 Antibody for Lupus Treatment(Post)Quick Facts About LitifilimabWhat is Litifilimab?Litifilimab is a monoclonal antibody developed by Biogen targeting BDCA2, a receptor on plasmacytoid dendritic cells (pDCs), to regulate
Microglial Functions Explained: Immunity, Inflammation & Neurodegeneration(Post)Neuroscience · NeuroimmunologyMicroglial Functions: Immunity, Inflammation & NeurodegenerationMicroglia are the resident immune cells of the central nervous system — dynamic sentinels that survey the
Ramucirumab: Mechanism, Clinical Applications, and Biosimilars in Cancer Research(Post)Quick Facts About RamucirumabWhat is Ramucirumab?Ramucirumab is a monoclonal antibody that targets vascular endothelial growth factor receptor 2 (VEGFR-2), inhibiting angiogenesis, a pro
Rovalpituzumab Tesirine: Advancing Small Cell Lung Cancer Research(Post)Quick Facts About Rovalpituzumab TesirineWhat is Rovalpituzumab Tesirine?Rovalpituzumab Tesirine (Rova-T) is an antibody-drug conjugate (ADC) designed to target DLL3, a protein overexpre
Narsoplimab: Targeting MASP-2 to Advance Therapies in Immune-Mediated Disorders(Post)Quick Facts About NarsoplimabWhat is Narsoplimab?Narsoplimab is a human monoclonal antibody that targets MASP-2, a key enzyme in the lectin pathway of the complement system.What is the m
Vorsetuzumab: Advancing Cancer Research with CD70 Targeting(Post)What You Need to Know About VorsetuzumabWhat is Vorsetuzumab?Vorsetuzumab is a monoclonal antibody targeting CD70, a protein found in various cancers. It shows promise for advancing canc
Turning Tumors Against Themselves: In Vivo Reprogramming of Cancer Cells into Dendritic Sentinels(Post)Imagine a future where cancer cells, once masters of disguise, are forced to reveal themselves and even train the body's immune system to fight back. This isn't science fiction; it's the groundbreaki
Talacotuzumab: Exploring CD123-Targeting Therapies in AML and MDS Research(Post)Key Facts About TalacotuzumabWhat is Talacotuzumab?Talacotuzumab is a monoclonal antibody designed to target CD123, a protein commonly found on the surface of certain blood cancer cells.
Gut Homing and Tissue-Resident Memory: How T Cells Stay Put(Post)A T cell does not choose which tissue to defend. The tissue chose it, during priming. A naive T cell has no tropism at all; it acquires one from the dendritic cell that activates it, and the instruct
Guselkumab: Advancing Psoriasis and Autoimmune Disease Research Through IL-23 Targeting(Post)Quick Facts About GuselkumabWhat is Guselkumab?Guselkumab is a biologic therapy that selectively targets the p19 subunit of interleukin-23 (IL-23), playing a critical role in inflammator
Tumor-Associated Macrophages: Double Agents in the Cancer Battlefield(Post)Tumor-Associated Macrophages: Double Agents in the Cancer Battlefield In the intricate theater of the human body, the immune system acts as a vigilant guardian, dispatching cellular soldiers to seek